XERS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Xeris Biopharma Holdings Inc (XERS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts such as improving revenue growth and a favorable analyst rating, the technical indicators, options data, and financial performance suggest a cautious approach. The lack of recent trading signals and the absence of significant news or influential trading activity further support a hold recommendation.
The MACD histogram is negative (-0.0373) and contracting, indicating weak momentum. RSI is neutral at 44.392, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 7.147, with resistance at 7.457 and support at 6.838, indicating limited short-term upside.
Revenue increased by 37.06% YoY in Q3
Gross margin improved to 81.57%, up 16.60% YoY.
Barclays initiated coverage with an Overweight rating and a $9 price target, citing improving investor sentiment and easing pricing headwinds in the sector.
Net income dropped significantly (-103.95% YoY), and EPS fell to 0 (-100% YoY).
The MACD and RSI suggest weak momentum.
No recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q3 2025, revenue grew by 37.06% YoY to $74.38M, and gross margin improved to 81.57%. However, net income dropped by -103.95% YoY to $621K, and EPS fell to 0 (-100% YoY), indicating profitability challenges.
Barclays initiated coverage with an Overweight rating and a $9 price target, highlighting opportunities in the specialty pharmaceuticals sector as pricing headwinds ease and companies focus on innovation and margin expansion.
